What is the drug class of desipramine and what are the recommended dosing guidelines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Desipramine: Drug Class and Dosing

Desipramine is a secondary-amine tricyclic antidepressant (TCA), and the recommended dosing for depression is 100 to 300 mg daily, with lower starting doses of approximately 50% in elderly patients. 1, 2

Drug Classification

Desipramine is classified as a tricyclic antidepressant (TCA), specifically a secondary-amine TCA 1, 2. This distinction is clinically important because secondary-amine TCAs (desipramine and nortriptyline) have lower affinity for muscarinic receptor antagonism compared to tertiary-amine TCAs (amitriptyline, imipramine), resulting in fewer anticholinergic side effects 1. This makes desipramine a safer choice than tertiary-amine TCAs, particularly in elderly patients where anticholinergic effects pose greater risks 1.

Standard Dosing Guidelines

Adult Dosing

  • Standard therapeutic range: 100 to 300 mg daily 1
  • Mean effective dose in clinical trials: approximately 150-200 mg/day 3, 4
  • Dosing typically requires titration upward from lower starting doses 2

Elderly Patients

  • Start at approximately 50% of the adult starting dose 1
  • Lower doses are specifically recommended due to:
    • Increased risk of adverse drug reactions 1
    • Decreased renal function (desipramine is substantially excreted by the kidney) 2
    • Increased ratio of 2-hydroxydesipramine to desipramine metabolite 2
    • Higher proneness to falls and confusional states 2

Dose Equivalency

Based on systematic analysis of randomized controlled trials, desipramine 196.3 mg/day is equivalent to fluoxetine 40 mg/day 5. This provides a reference point when switching between antidepressants.

Critical Safety Considerations

Cardiovascular Monitoring Required

Extreme caution is mandatory in patients with:

  • Cardiovascular disease (risk of conduction defects, arrhythmias, tachycardias, stroke, acute MI) 2
  • Family history of sudden death, cardiac dysrhythmias, or cardiac conduction disturbances 2
  • Desipramine has a quinidine-like effect on cardiac arrhythmias but should be used with caution in patients at risk of heart block and bundle branch block 6

Important Contraindications and Warnings

  • Avoid in patients with urinary retention or glaucoma due to anticholinergic properties 2
  • Use cautiously in thyroid disease or patients on thyroid medication (cardiovascular toxicity risk) 2
  • Lower seizure threshold—seizures may precede cardiac dysrhythmias and death 2
  • Can block antihypertensive effects of guanethidine 2

Notable Safety Concern

Desipramine has a significantly higher case fatality rate than other TCAs—2.25-fold higher than amitriptyline, 2.31-fold higher than nortriptyline, and 2.62-fold higher than imipramine (P < 0.001) 7. This excess mortality may relate to dosing recommendations that have not been adjusted downward despite desipramine having higher distribution volumes than its parent compound imipramine 7.

Pharmacogenetic Considerations

CYP2D6 genotype significantly affects desipramine metabolism 8. Poor metabolizers (PM) have substantially elevated drug levels and increased risk of:

  • Toxic blood levels 8
  • Lower tolerability 8
  • Serious adverse events including blood pressure changes, QT prolongation, seizures, and death 8

Consider dose reduction in CYP2D6 poor metabolizers or when co-administering CYP2D6 inhibitors 8.

Duration of Treatment

Continue treatment for 4 to 12 months after first episode of major depression 1. Patients with recurrent depression (≥3 episodes) benefit from prolonged maintenance treatment, as discontinuation significantly increases relapse risk 1.

Common Pitfalls to Avoid

  1. Do not use standard adult doses in elderly patients—always start at 50% of adult dose 1
  2. Monitor renal function in elderly patients—desipramine is renally excreted 2
  3. Do not overlook cardiovascular screening—obtain baseline ECG in at-risk patients 2, 6
  4. Avoid alcohol—potentiation increases danger in suicide attempts or overdosage 2
  5. Be aware of higher fatality risk—desipramine has the highest case fatality rate among TCAs 7

References

6
Research

Use of desipramine in the medically ill.

The Journal of clinical psychiatry, 1984

7
Research

Excess fatality from desipramine and dosage recommendations.

Therapeutic drug monitoring, 2004

Related Questions

What fluoxetine (Prozac) dose is equivalent to sertraline 200 mg daily?
What dose of bupropion (Wellbutrin) is equivalent to 20 mg of escitalopram (Lexapro)?
In a 20-year-old male with depression and anxiety who stopped escitalopram (Lexapro) because of side effects, what alternative medication options are appropriate?
In a 74-year-old male nursing home resident with chronic delusional disorder, depression, insomnia, and epilepsy treated with duloxetine 60 mg daily and levetiracetam 1000 mg twice daily, who now has active delusions causing intrusive and impulsive behaviors, what is the best psychotropic intervention to manage his symptoms while minimizing fall risk?
What is the equivalent dose of Wellbutrin (bupropion) for a patient taking 10mg of Lexapro (escitalopram)?
What is the appropriate non‑operative management for an uncomplicated boxer's fracture of the fifth metacarpal?
Can aripiprazole (Abilify) cause prolonged QT interval?
In an adult patient presenting with shoulder pain and imaging showing cystic changes at the attachment of the infraspinatus, what is the recommended management?
What is the appropriate workup and management for a patient with anemia of chronic disease and left‑shift leukocytosis?
Can a female patient who cannot tolerate statins or ezetimibe (Zetia) be prescribed evolocumab (Repatha) given a serum sodium of 145 mmol/L and a total cholesterol of 165 mg/dL?
Should we order a hanging‑drop wet mount or request special stains (modified acid‑fast or auramine) for Cryptosporidium and Cyclospora on the stool sample?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.